Fox Run Management L.L.C. Purchases 32,579 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Fox Run Management L.L.C. increased its holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 199.0% during the 4th quarter, Holdings Channel reports. The firm owned 48,950 shares of the biopharmaceutical company’s stock after buying an additional 32,579 shares during the period. Fox Run Management L.L.C.’s holdings in Sage Therapeutics were worth $266,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of SAGE. Picton Mahoney Asset Management grew its position in shares of Sage Therapeutics by 126.0% in the 4th quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 3,581 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Sage Therapeutics in the fourth quarter worth $49,000. Ieq Capital LLC bought a new stake in Sage Therapeutics in the fourth quarter valued at $57,000. US Bancorp DE increased its position in Sage Therapeutics by 22.3% during the 4th quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 2,268 shares during the period. Finally, Teacher Retirement System of Texas increased its position in Sage Therapeutics by 21.6% during the 4th quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company’s stock valued at $75,000 after purchasing an additional 2,446 shares during the period. Hedge funds and other institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Stock Up 0.7 %

Shares of NASDAQ SAGE opened at $8.66 on Friday. The firm has a market cap of $532.43 million, a P/E ratio of -1.31 and a beta of 0.82. Sage Therapeutics, Inc. has a twelve month low of $4.62 and a twelve month high of $19.34. The company has a 50 day moving average of $7.45 and a 200 day moving average of $6.73.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. As a group, equities analysts expect that Sage Therapeutics, Inc. will post -3.52 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Scotiabank cut their target price on shares of Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating on the stock in a research note on Wednesday, February 12th. Stifel Nicolaus cut their price objective on Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating on the stock in a research report on Monday, December 16th. Canaccord Genuity Group decreased their target price on Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating for the company in a research report on Wednesday, February 12th. HC Wainwright restated a “neutral” rating and set a $12.00 price target (down from $14.00) on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Finally, Piper Sandler reduced their price target on Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, January 2nd. Three analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $8.81.

Sage Therapeutics Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.